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Abstract
Introduction: Fulminant pulmonary embolism (PE) may lead to cardiogenic shock or cardiac arrest with high mortality rates (65%) 
despite treatment with thrombolysis. Patients not responding to this therapy might benefit from extracorporeal life support (ECLS). 
Only occasional case reports of ECLS in PE patients are available. We studied the use of ECLS after thrombolysis in patients 
suffering from refractory cardiogenic shock due to PE. 
Material and methods: Patients who were admitted to our university intensive care unit (ICU) with PE, not responding to throm-
bolysis, and who received subsequent ECLS treatment were studied. 
Results: 12 patients with severe PE were included. 6 patients were admitted by emergency medical services, 5 patients were 
transferred to the ICU from other hospitals and one patient presented at the emergency department by herself. 11 of 12 patients 
suffered from cardiac arrest and needed cardiopulmonary resuscitation (CPR) before ECLS implantation. Three ECLS were im-
planted during CPR and nine ECLS were implanted during emergency conditions in patients with cardiogenic shock. All patients 
received thrombolysis before implementation of ECLS. Mean duration of ICU treatment was 22.4 ± 23.0 days. Mean duration of 
ECLS therapy was 5.6 ± 6.5 days. Bleeding complications occurred in four patients. Complications directly related to the ECLS 
system occurred in two patients (overall complication rate 42%). Overall, 6 of 12 patients (50%) survived.
Conclusions: ECLS may be considered as a bailout therapy in PE patients not responding to prior definitive treatment such as 
thrombolysis. ECLS therapy seems to be feasible with an acceptable complication rate even after thrombolysis. 
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failure
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Introduction
Fulminant pulmonary embolism (PE) is a po-
tential hazardous disease. Pulmonary artery occ-
lusion by thromboembolism may lead to oxyge-
nation and/or right heart failure. Patients with PE 
suffering from cardiogenic shock or cardiac arrest 
have high mortality rates (65%) [1, 2].
Treatment options range from simple anti-
coagulation to definitive treatment options such 
as local or systemic thrombolysis, surgical em-
bolectomy and catheter-based therapies. In cases 
with severe cardiogenic shock or cardiac arrest, 
immediate thrombolysis is often performed. Since 
1995, only a  few cases were reported in which 
extracorporeal membrane oxygenation (ECMO)/ 
/extracorporeal life support (ECLS) were applied 
either in combination with the above mentioned 
treatment options or alone [3].
However, in some patients who do not re-
spond to the definitive treatment options men-
tioned above, ECLS might be the only life-saving 
therapy. In these patients, ECLS can be used as 
a bridge to right heart recovery. Data on the use 
of ECLS after treatment of PE with thrombolysis, 
surgical embolectomy or catheter based techniqu-
es are rare [4]. The recently updated ESC (Europe-
an Society of Cardiology) guidelines from 2019 
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for the treatment of PE recommend that “ECMO 
may be considered, in combination with surgical 
embolectomy or catheter-directed treatment, in 
patients with PE and refractory circulatory col-
lapse or cardiac arrest” [5]. This recommendation 
is classified as class IIb and level C [5]. The use 
of ECLS in high-risk PE patients as a stand-alone 
technique with anticoagulation is deemed to be 
controversial and as such, the ESC guidelines 
suggest considering additional therapies, such 
as surgical embolectomy or catheter-directed 
treatment [5].
We conducted a study in high-risk patients 
suffering from cardiogenic shock due to PE 
despite thrombolysis with subsequent need for 
ECLS therapy. 
Material and methods
Our study was performed according to the 
Declarations of Helsinki. Due to the retrospecti-
ve nature of the study, a full review by the local 
Ethics Committee was not required.
We retrospectively enrolled 12 consecutive 
patients that were admitted to the ICU of the 
University Hospital of Muenster with fulminant 
pulmonary embolism who did not respond to 
thrombolysis and were treated with ECLS.
ECLS was implanted if return of spontaneo-
us circulation (ROSC) could not be achieved 
during CPR after systemic thrombolysis, if shock 
symptoms and hypotension did not recede after 
thrombolysis, and in one patient due to severe 
shock and progressive lactic acidosis with a ra-
pidly rising need for vasopressors.
For ECLS we used Rotaflow or Cardiohelp 
systems (Maquet, Rastatt, Germany). Cannulas 
(Novalung, Heilbronn, Germany and Maquet, 
Rastatt, Germany) were sized 15F–23F, if ap-
propriate. Cannulas were placed via the femoral 
vein and femoral artery in most cases. In two ca-
ses, the subclavian artery was used via surgically 
implanted patches.
Thrombolysis was performed using either 
8000 IU tenecteplase or 100mg of rtPA with prior 
application of 5000 IU heparin. 
We analyzed demographic parameters of 
the study cohort as well as the following data: 
duration of ICU treatment, duration of ECLS tre-
atment, need for cardiopulmonary resuscitation, 
circumstances of ECLS implantation (during CPR 
or emergency setting), ECLS associated compli-
cations, mode of ICU admission, and survival.
Study cohort characteristics
Our study cohort involved 12 patients 
(3 females) with a mean age of 44.2 ± 11.9 years 
(Table 1). 
With regard to pre-existing diseases, one pa-
tient had a congenital heart defect with a hypo-
plastic right ventricle, pulmonary valve stenosis 
and a secundum atrial septal defect which was 
previously treated with a modified Fontan opera-
tion. Another patient suffered from dilative car-
diomyopathy. One patient had a factor V Leiden 
mutation with recurrent deep vein thrombosis 
and former oral anticoagulation therapy. Lastly, 
one patient had a myeloproliferative disease. 
Table 1.  Study cohort characteristics. Summary of study cohort characteristics concerning gender, age, duration of stay 
on intensive care unit (ICU), duration of extracorporeal life support (ECLS) treatment, need for cardiopulmonary 
resuscitation (CPR), complications after thrombolysis and ECLS implantation, time point of thrombolysis and 
survival
Patients (n) 12
Male 9 (75%)
Age (years) 44.2 ± 11.9
ICU duration (days) 22.4 ± 23
ECLS duration (days) 5.6 ± 6.5
CPR before ECLS implantation 11 (92%), 7 in-hospital, 4 out-of-hospital
CPR during ECLS implantation 3 (25%)
ECLS associated complications 5 (42%)
Time of thrombolysis 4 out-of-hospital, 6 in-hospital, 2 local via catheter into pulmonary artery
Overall survival 6 (50%)
CPR — cardiopulmonary resuscitation; ECLS — extracorporeal life support; ICU — intensive care unit
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Confirmation of diagnosis
Assumed admission diagnosis of all 12 
patients was severe pulmonary embolism. In 
7 patients, pulmonary embolism was confirmed 
by contrast-enhanced computed tomography 
(CT). In the remaining 5 patients, PE was assumed 
due to clinical presentation and severe right heart 
dilatation detected by echocardiography.
In one of these five patients, echocardio-
graphy detected a  large thrombus in the right 
atrium protruding into the right ventricle. 
Circumstances of admission and ECLS 
implantation
6 patients were admitted to the ICU by the 
emergency medical service. Further, 5 patients 
were subsequently transferred to our ICU from 
other hospitals. One patient presented at our 
emergency department by herself.
11 of 12 patients suffered from cardiac ar-
rest and received CPR of different duration prior 
to ECLS implantation (Table 1). Seven of these 
11 patients suffered from in-hospital cardiac 
arrest and four had an out-of-hospital cardiac 
arrest (OHCA) (Table 1). In one of the four OHCA 
patients, the emergency medical service team 
achieved out of hospital return of spontaneous 
circulation (ROSC). The remaining three OHCA 
patients were transported under ongoing CPR. 
In two of these three patients, ECLS was imple-
mented during continuous CPR in our ICU. One 
of the three patients had intra-hospital ROSC and 
received ECLS subsequently due to persistent 
hemodynamic instability. 
In total, three of the ECLS systems were 
implanted during ongoing cardiopulmonary re-
suscitation and the remaining nine ECLS systems 
were implanted during emergency conditions in 
critically hemodynamically unstable patients. 
Only one patient received ECLS without prior 
resuscitation due to progressive shock.
ICU and drug treatment
All patients received systemic or local throm-
bolysis before implementation of ECLS (Table 1). 
Four patients received systemic thrombolysis 
out-of-hospital and six patients received syste-
mic thrombolysis intra-hospital. Two patients 
received local thrombolysis via pulmonary artery 
catheterization. In addition, two of the 12 patients 
were additionally treated with pulmonary cathe-
ter fragmentation.
During ECLS implantation, 11 patients were 
intubated and mechanically ventilated. One pa-
tient not requiring CPR was awake during ECLS 
implementation and received analgosedation. 
The venous cannula was inserted into 
the vena femoralis in all patients. The arterial 
cannula was placed in the arteria femoralis in 
10 patients. In 2 patients, the arterial cannula was 
placed surgically into the arteria subclavia dextra. 
ICU course and complications
Mean duration of ICU treatment was 
22.4 ± 23.0 days. ECLS therapy was performed 
with a mean duration of 5.6 ± 6.5 days.
After thrombolysis and subsequent imple-
mentation of ECLS, bleeding complications occu-
rred in four patients. One patient showed minor 
bleeding at the arterial cannula placed in the 
arteria subclavia. Further, two patients had minor 
bleedings at the cannulas as well as gastrointesti-
nal bleeding. During ECLS treatment, one patient 
showed major bleeding with subsequent femoral 
compartment syndrome. One of these patients 
also suffered from initially accidental mispla-
cement of the venous cannula into the arteria 
femoralis during ECLS implantation with need 
for immediate surgical revision. Additionally, one 
patient developed an arteriovenous fistula with 
need for surgical therapy in the further course 
(Table 1).
In all surviving patients, ECLS was extracted 
without need for re-implantation. 
Outcome
6 of 12 patients (50%) died during treatment. 
5 patients died due to multi-organ failure and 
lactic acidosis after prolonged CPR. Three of 
these five patients had out-of-hospital cardiac 
arrest with CPR during transport to the hospital. 
In addition, one patient died during long-term 
ICU stay due to sclerosing cholangitis. This 
patient had presented herself at the emergency 
department and did not require CPR. The other 
6 of 12 patients (50%) were discharged from ho-
spital (Table 1). 
Discussion
For prognostic reasons and therapeutic deci-
sion making, PE is often classified as high risk, 
intermediate risk, and low risk PE [5, 6]. Patients 
with low and intermediate risk PE should receive 
anticoagulation only. Patients with cardiac arrest 
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or severe shock due to pulmonary embolism should 
be treated with thrombolysis with adherence to 
individual contraindications such as recent in-
tracerebral bleeding. The PEITHO study showed 
that patients with even an intermediate risk PE 
had a lower risk of hemodynamic decompensation 
when treated with thrombolysis. However, they had 
an elevated risk of major hemorrhage or stroke [7]. 
Due to advances regarding ECLS therapy (i.e. 
improved pump technology and coated tubes), 
ECLS systems have been developed that can be 
rapidly applied even in patients in severe shock 
or during CPR via femoral vein and artery access 
[8]. ECLS has already been reported as a  sup-
portive measure in patients undergoing surgical 
thrombectomy [9]. During the last few years, 
implementation of ECLS due to refractory cardiac 
arrest is increasingly used. This procedure is so 
far called eCPR (extracorporeal cardiopulmonary 
resuscitation) and is known to increase survival 
rates in selected patients [10]. Therefore, in pa-
tients with massive PE and severe shock despite 
definitive treatment by thrombolysis and catheter 
fragmentation, ECLS can be used as a bailout stra-
tegy. A review by Yusuff et al. reported 43 patients 
receiving ECLS for refractory cardiac arrest due 
to PE with an overall survival of 51.2% [3]. In 
a subgroup of 21 patients treated with ECLS and 
thrombolysis or catheter embolectomy, survival 
rate was 43%. Another study reported 17 patients 
treated with fibrinolysis and ECMO having a 30 
day survival rate of 23.5% [11]. In addition, a stu-
dy by Corsi et al. [12] reported thrombolysis in 
8 of 17 patients with fulminant PE before ECLS 
was implemented. Overall, 90 day survival of the 
17 PE patients treated with ECLS was 47% [12]. In 
our study, patients pretreated with thrombolysis 
and subsequent ECLS therapy had a survival rate 
of 50% until hospital discharge. In our universi-
ty hospital, we perform around 50 ECMO/ECLS 
implantations per year. Around 10 percent of 
ECMO/ECLS are implanted during ongoing CPR. 
A trained ECMO/ECLS team for implantation is 
permanently available. Due to these conditions, 
the experience of our center might also contribute 
to the improved survival rate in our study cohort. 
In comparison, other studies showed a range 
of survival rates between 35–52% in patients with 
PE and cardiogenic shock or cardiac arrest treated 
with fibrinolysis or embolectomy but without 
ECLS treatment [1, 2, 11]. When comparing these 
studies to our study, ECLS therapy may be useful 
and points to improved survival in a subgroup of 
patients with high risk PE and failure of throm-
bolysis and embolectomy. 
Further, the review by Yusuff et al. found an 
ECLS related complication rate of 37% (16/43 
patients) [3]. Another study with 52 patients 
being treated with only ECLS therapy or ECLS 
therapy in combination with thrombolysis and 
embolectomy found that major bleeding events 
occurred in 20 patients (38.5%) [11]. In addition, 
Corsi et al. [12] found severe hemorrhages with 
no impact on survival in 15 of 17 patients (88%) 
with a median of 4 packed red-cell and 5 fresh
-frozen plasma units transfused. Surgical wound 
infections are reported in 9.6% of PE patients 
treated with ECLS [11]. In our study, we had 
a complication rate of 17% directly related to the 
ECLS (misplacement of one cannula and arterio-
venous fistula, 2/12 patients). One of these two 
patients and an additional three other patients 
had bleeding complications after thrombolysis 
and ECLS implantation, which is a typical side 
effect after thrombolysis. By summarizing the 
complications due to thrombolysis and ECLS 
implantation, we observed a complication rate of 
42% which is comparable to the reported compli-
cation rate by other studies [3, 11, 12]. Therefore, 
ECLS implantation seems to be feasible in the 
subgroup of high-risk PE patients pretreated with 
thrombolysis.
In our study, the mean duration of ICU stay 
was 22.5 ± 23 days, which is comparable to 
another study with 19 ± 14.6 days [3]. Duration 
of ECLS treatment in our patient cohort was 
relatively short with 5.6 ± 6.5 days and is in 
a similar range when comparing with other re-
ports (2.5–4.5 days) [3, 11, 12]. Duration of ECLS 
therapy in patients with severe PE seems to be 
briefer in relation to patients treated with ECMO 
due to severe acute respiratory distress syndrome 
(ARDS) within 9–15 days of ECMO support [13]. 
This relatively short ECLS treatment duration in 
PE patients may be due to thrombus dissolution 
by continuous heparin application together with 
spontaneous thrombolysis [12]. 
In our study, as expected, the main cause of 
death in non-survivors (5/12 patients) was multi
-organ failure, which was similarly the cause of 
death found in other studies [3, 11, 12]. In our 
study more than half of the patients were resusci-
tated outside of the hospital, which is a patient 
subgroup with a known worse outcome.
Conclusions
We therefore postulate that ECLS should be 
considered as a bailout therapy in PE patients 
not responding to prior definitive treatment such 
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as thrombolysis. Further, ECLS therapy seems to 
be feasible with an acceptable complication rate 
even after thrombolysis against the background 
of lacking therapy alternatives in this subgroup 
of patients. Our results may indicate an improved 
survival rate in this subgroup of PE patients. The-
refore, further studies and randomized controlled 
trials are required to confirm the usefulness of 
ECLS therapy in patients with severe PE even 
without definitive treatment such as thrombolysis 
but instead, only anticoagulation. 
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